Dr. Sara M. Lewin, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 299
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of California, San Francisco School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A127107 (first issued 2013; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
- Marinhealth Medical Center Greenbrae, CA
- Adventist Health Howard Memorial Willits, CA
Medical groups
- UCSF Medical Group Business Services (1,598 clinicians)
- Regents of the University of California (732 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 299
- Services billed
- 3,859
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 101 | 73 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 54 | 54 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 49 | 47 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 48 | 47 |
| Biopsy of large bowel using a flexible endoscope | 29 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 17 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 16 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in San Francisco, CA | 54 |
| Dicyclomine Hcl Other prescribers in San Francisco, CA | 26 |
| Famotidine Other prescribers in San Francisco, CA | 20 |
| Colesevelam Hcl Other prescribers in San Francisco, CA | 19 |
| Xifaxan (rifaximin) Other prescribers in San Francisco, CA | 18 |
| Fluconazole Other prescribers in San Francisco, CA | 18 |
| Mirtazapine Other prescribers in San Francisco, CA | 13 |
| Mesalamine Other prescribers in San Francisco, CA | 13 |
| Skyrizi On-Body (risankizumab-rzaa) | 12 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in San Francisco, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $173,354 in research payments for these studies, mostly to the institutions running them.
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)
Janssen Research & Development, LLC - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
F. Hoffmann-la Roche AG - UC P3: Double-Blind Treat Straight Through
Genentech, Inc. - M24-144 - A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
AbbVie Inc. - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
Genentech, Inc. - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.